High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia.
High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia.
复制标题
DOI:
10.1371/journal.pone.0051527
复制
发表时间:
2012
期刊:
影响因子:
3.7
通讯作者:
Michallet M
中科院分区:
文献类型:
--
作者:
Hayette S;Thomas X;Jallades L;Chabane K;Charlot C;Tigaud I;Gazzo S;Morisset S;Cornillet-Lefebvre P;Plesa A;Huet S;Renneville A;Salles G;Nicolini FE;Magaud JP;Michallet M
It has been recently shown that DNA methyl transferase overexpression is correlated with unfavourable prognosis in human malignancies while methylation deregulation remains a hallmark that defines acute myeloid leukemia (AML). The oncogenic transcription factor EVI1 is involved in methylation deregulation and its overexpression plays a major role for predicting an adverse outcome. Moreover, the identification of DNMT3A mutations in AML patients has recently been described as a poor prognostic indicator. In order to clarify relationship between these key actors in methylation mechanisms and their potential impact on patient outcomes, we analysed 195 de novo AML patients for the expression of DNMT3A, 3B (and its non-catalytic variant 3BNC) and their correlations with the outcome and the expression of other common prognostic genetic biomarkers (EVI1, NPM1, FLT3ITD/TKD and MLL) in adult AML. The overexpression of DNMT3B/3BNC is (i) significantly correlated with a shorter overall survival, and (ii) inversely significantly correlated with event-free survival and DNMT3A expression level. Moreover, multivariate analysis showed that a high expression level of DNMT3B/3BNC is statistically a significant independent poor prognostic indicator. This study represents the first report showing that the overexpression of DNMT3B/3BNC is an independent predictor of poor survival in AML. Its quantification should be implemented to the genetic profile used to stratify patients for therapeutical strategies and should be useful to identify patients who may benefit from therapy based on demethylating agents.
登录
查看更多内容
影响因子:
50.3
作者:
Figueroa ME;Abdel-Wahab O;Lu C;Ward PS;Patel J;Shih A;Li Y;Bhagwat N;Vasanthakumar A;Fernandez HF;Tallman MS;Sun Z;Wolniak K;Peeters JK;Liu W;Choe SE;Fantin VR;Paietta E;Löwenberg B;Licht JD;Godley LA;Delwel R;Valk PJ;Thompson CB;Levine RL;Melnick A
通讯作者:
Melnick A
影响因子:
64.5
作者:
Okano, M;Bell, DW;Li, E
通讯作者:
Li, E
DOI:
10.1056/nejmoa1005143
发表时间:
2010-12-16
期刊:
The New England journal of medicine
影响因子:
--
作者:
Ley TJ;Ding L;Walter MJ;McLellan MD;Lamprecht T;Larson DE;Kandoth C;Payton JE;Baty J;Welch J;Harris CC;Lichti CF;Townsend RR;Fulton RS;Dooling DJ;Koboldt DC;Schmidt H;Zhang Q;Osborne JR;Lin L;O'Laughlin M;McMichael JF;Delehaunty KD;McGrath SD;Fulton LA;Magrini VJ;Vickery TL;Hundal J;Cook LL;Conyers JJ;Swift GW;Reed JP;Alldredge PA;Wylie T;Walker J;Kalicki J;Watson MA;Heath S;Shannon WD;Varghese N;Nagarajan R;Westervelt P;Tomasson MH;Link DC;Graubert TA;DiPersio JF;Mardis ER;Wilson RK
通讯作者:
Wilson RK
影响因子:
56.9
作者:
RAZIN, A;RIGGS, AD
通讯作者:
RIGGS, AD
影响因子:
16
作者:
Palakurthy RK;Wajapeyee N;Santra MK;Gazin C;Lin L;Gobeil S;Green MR
通讯作者:
Green MR